|
Sign In to gain access to subscriptions and/or personal tools.
|
Three screening batteries to detect cognitive impairment in multiple sclerosis
R L Aupperle
Departments of Psychiatry and Behavioral Sciences and Neurology, University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, Oklahoma 73190, USA
W W Beatty
Departments of Psychiatry and Behavioral Sciences and Neurology, University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, Oklahoma 73190, USA, william-beatty{at}ouhsc.edu
F deNAP Shelton
Departments of Psychiatry and Behavioral Sciences and Neurology, University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, Oklahoma 73190, USA
S T Gontkovsky
Departments of Psychiatry and Behavioral Sciences and Neurology, University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, Oklahoma 73190, USA
To compare the sensitivities for detecting cognitive impairment in patients with multiple sclerosis (MS) and administration times of three brief batteries of neuropsychological tests, 64 patients with MS completed the Neuropsychological Screening Battery for Multiple Sclerosis (NPSBMS), the Screening Examination for Cognitive Impairment (SEFCI), and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Failure on a particular test was defined as a score below the 5th percentile for healthy controls, and the number of patients who failed at least one or two tests (out of four) was determined for each battery. Both the SEFCI and the NPSBMS identified significantly more patients with impairment than the RBANS, which was no more sensitive than the Mini-Mental State Exam (MMSE). Results were similar at both the one- and two-failed-tests criteria, but there were no significant differences between the SEFCI and the NPSBMS at either failure criterion. Mean administration time was 22.6 min for the SEFCI compared to 31.7 min for the NPSBMS (p <0.001). Eleven (17%) of the patients refused to attempt the Paced Auditory Serial Addition Test (PASAT), one component of the NPSBMS. For screening patients on a single occasion, the SEFCI is preferred because its administration time is shorter than the NPSBMS.
Key Words: cognition demyelinating disease information processing memory multiple sclerosis screening batteries
Multiple Sclerosis, Vol. 8, No. 5,
382-389 (2002)
DOI: 10.1191/1352458502ms832oa

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Drake, B. Weinstock-Guttman, S. Morrow, D. Hojnacki, F. Munschauer, and R. Benedict
Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test
Multiple Sclerosis,
February 1, 2010;
16(2):
228 - 237.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E Portaccio, B Goretti, S Lori, V Zipoli, S Centorrino, A Ghezzi, F Patti, V Bianchi, G Comi, M Trojano, et al.
The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis
Multiple Sclerosis,
May 1, 2009;
15(5):
620 - 626.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
N Figved, R Benedict, G Klevan, K. Myhr, H. Nyland, N. Landro, J. Larsen, and D Aarsland
Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis
Multiple Sclerosis,
September 1, 2008;
14(8):
1084 - 1090.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Younes, J. Hill, J. Quinless, M. Kilduff, B. Peng, S. Cook, and D. Cadavid
Internet-based cognitive testing in multiple sclerosis
Multiple Sclerosis,
September 1, 2007;
13(8):
1011 - 1019.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Solari, A. Motta, D. Radice, and L. Mendozzi
A shortened version of PASAT-3 is feasible
Multiple Sclerosis,
September 1, 2007;
13(8):
1020 - 1025.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Scherer, I.K. Penner, A. Rohr, H. Boldt, I. Ringel, H. Wilke-Burger, E. Burger-Deinerth, K. Isakowitsch, M. Zimmermann, S. Zahrnt, et al.
The Faces Symbol Test, a newly developed screening instrument to assess cognitive decline related to multiple sclerosis: first results of the Berlin Multi-Centre FST Validation Study
Multiple Sclerosis,
April 1, 2007;
13(3):
402 - 411.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
I M Claesson, C Ytterberg, S Johansson, O Almkvist, and L von Koch
Rapid cognitive screening in multiple sclerosis accomplished by the Free Recall and Recognition Test
Multiple Sclerosis,
March 1, 2007;
13(2):
272 - 274.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M S. Deloire, M C Bonnet, E Salort, Y Arimone, M Boudineau, K G Petry, and B Brochet
How to detect cognitive dysfunction at early stages of multiple sclerosis?
Multiple Sclerosis,
August 1, 2006;
12(4):
445 - 452.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J Sepulcre, S Vanotti, R Hernandez, G Sandoval, F Caceres, O Garcea, and P Villoslada
Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test
Multiple Sclerosis,
April 1, 2006;
12(2):
187 - 195.
[Abstract]
[PDF]
|
 |
|
|
|